ClinicalTrials.gg
Drug

Sapanisertib clinical trials

Also written MLN0128 and TAK-228.

studies test it
47
open now
3
in phase 3
0
first study started
2010

How each study uses sapanisertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sapanisertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sapanisertib
27

Development codes

MLN0128
37
TAK-228
33
INK128
27
FTH-003
1
CB-228
1

Studies by the year they started

47 studies that test it; most in 2017 (13)

Studies that test sapanisertib, by start year
YearStudies
20102
20111
20131
20145
20154
20167
201713
20186
20203
20211
20221
20241
20251
20261

Who runs them

Industry 12 · Other 35

National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (7) · Millennium Pharmaceuticals, Inc. (6) · Calithera Biosciences, Inc (3) · Faeth Therapeutics (3) · Dana-Farber Cancer Institute (2) · Imperial College London (1) · Avera McKennan Hospital & University Health Center (1)

Often tested with

Tested in the same studies.

Serabelisib (7) · Paclitaxel (5) · Telaglenastat hydrochloride (1) · Adavosertib (1) · Afatinib (1) · Binimetinib (1) · Capivasertib (1) · Copanlisib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test sapanisertib.

Studies

Open first, then newest update. How each study uses sapanisertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 47

See all 47 studies that test sapanisertib →

Given beside what is tested · 3 — sapanisertib is usual care or a partner of the new treatment

Codes

What other systems call sapanisertib · ClinicalTrials.gg INT006065

  • MeSH (NLM) C572449sapanisertibOne source NLM
  • UNII (FDA) JGH0DF1U03SAPANISERTIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2395271One source FDA
  • Wikidata Q27078072sapanisertibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C90548SapanisertibOne source FDA
  • DrugBank DB11836One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.